Brazil signs agreement to produce AstraZeneca's experimental Covid-19 vaccine

China approves coronavirus drug for limited use

WHO wants $18 billion in race for vaccine

But CanSino said that it can not guarantee that the vaccine, which has undergone both phase one and two clinical trials in China, will ultimately be commercialised.

China National Biotec Group (CNBG) said on Sunday that early human test results for a coronavirus vaccine candidate suggested it could be safe and effective, the second vaccine candidate from the firm to show encouraging results in a clinical trial.

CanSino revealed it had received a certificate from China's National Medical Products Administration to launch clinical trials.

Hong Kong-listed CanSino Biologics said in a filing to the stock exchange that data from clinical trials showed the Chinese military vaccine had a "good safety profile" and potential to prevent disease caused by the coronavirus.

CanSino declined to disclose whether the inoculation of the vaccine candidate is mandatory or optional, citing commercial secrets, in an email to Reuters.

As of Monday, the country had tallied 1.35 million cases of COVID-19 and almost 58,000 deaths, according to case tracker Worldometers.

Now, China's Central Military Commission has approved the use of the drug by the military on June 25th for one year. But for the United States or China, it would also be a massive geopolitical victory.

There are now 224 candidate vaccines in development globally, according to the data collected by the Coalition for Epidemic Preparedness Innovations (CEPI). Responding to queries on leading vaccine candidates, Swaminathan said AstraZeneca has the largest global commitment and was the leading candidate in terms of timing. This appears to be the first coronavirus vaccine to be made widely available to a segment of a population before finishing Phase 3 trials.

Since first appearing in China last December, the virus has spread to at least 188 countries and regions.

Latest News